US5356887A
(en)
*
|
1990-01-31 |
1994-10-18 |
Merck & Co., Inc. |
Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
|
US5019651A
(en)
*
|
1990-06-20 |
1991-05-28 |
Merck & Co., Inc. |
Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
|
US5039819A
(en)
*
|
1990-09-18 |
1991-08-13 |
Merck & Co., Inc. |
Diphosphonate intermediate for preparing an antihypercalcemic agent
|
US5159108A
(en)
*
|
1990-09-18 |
1992-10-27 |
Merck & Co., Inc. |
Process for preparing an antihypercalcemic agent
|
US5763611A
(en)
*
|
1992-05-29 |
1998-06-09 |
The Procter & Gamble Company |
Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
|
HUT69731A
(en)
*
|
1992-05-29 |
1995-09-28 |
Procter & Gamble Pharma |
Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism
|
US5753634A
(en)
*
|
1992-05-29 |
1998-05-19 |
The Procter & Gamble Company |
Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
|
US5391743A
(en)
*
|
1992-05-29 |
1995-02-21 |
Procter & Gamble Pharmaceuticals, Inc. |
Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
|
ATE195317T1
(de)
*
|
1992-05-29 |
2000-08-15 |
Procter & Gamble Pharma |
Schwefel-enthaltende phosphonat-verbindungen zur behandlung von abnormalem calzium- und phosphat- metabolismus
|
DK0646119T3
(da)
*
|
1992-05-29 |
1998-12-14 |
Procter & Gamble Pharma |
Phosphonatforbindelser indeholdende kvaternært nitrogen til behandling af unormalt calcium- og phosphatstofskifte samt tan
|
FR2694558B1
(fr)
*
|
1992-08-05 |
1994-10-28 |
Sanofi Elf |
Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
|
US6406714B1
(en)
|
1992-12-02 |
2002-06-18 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids
|
US6399592B1
(en)
|
1992-12-23 |
2002-06-04 |
Merck & Co., Inc. |
Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
|
FR2703590B1
(fr)
*
|
1993-04-05 |
1995-06-30 |
Sanofi Elf |
Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
|
TW257765B
(pt)
*
|
1993-08-25 |
1995-09-21 |
Merck & Co Inc |
|
US5510517A
(en)
*
|
1993-08-25 |
1996-04-23 |
Merck & Co., Inc. |
Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
|
US5854227A
(en)
*
|
1994-03-04 |
1998-12-29 |
Hartmann; John F. |
Therapeutic derivatives of diphosphonates
|
US20010007863A1
(en)
*
|
1998-06-18 |
2001-07-12 |
Merck & Co., Inc. |
Wet granulation formulation for bisphosphonic acids
|
US5462932A
(en)
*
|
1994-05-17 |
1995-10-31 |
Merck & Co., Inc. |
Oral liquid alendronate formulations
|
US5449819A
(en)
*
|
1994-06-06 |
1995-09-12 |
Merck & Co., Inc. |
Process for removing waste pox, alendronate and its by products
|
US5589691A
(en)
*
|
1994-06-06 |
1996-12-31 |
Merck & Co., Inc. |
Process for recovery and recycle of methanesulfonic acid and phosphorous acid
|
US5780455A
(en)
*
|
1994-08-24 |
1998-07-14 |
Merck & Co., Inc. |
Intravenous alendronate formulations
|
CN1181012A
(zh)
*
|
1995-02-17 |
1998-05-06 |
麦克公司 |
减小非椎骨骨折危险的方法
|
EP0824341A4
(en)
*
|
1995-05-12 |
1999-07-07 |
Merck & Co Inc |
PREVENTING TOOTH LOSS THROUGH ADMINISTRATION OF ALENDRONATE OR ITS SALTS
|
JPH11506757A
(ja)
*
|
1995-06-06 |
1999-06-15 |
メルク エンド カンパニー インコーポレーテッド |
二ナトリウムアレンドロネート製剤
|
WO1996039107A1
(en)
|
1995-06-06 |
1996-12-12 |
Merck & Co., Inc. |
Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
|
DK0833643T3
(da)
*
|
1995-06-06 |
2005-05-30 |
Merck & Co Inc |
Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
|
TR199900730T2
(xx)
*
|
1996-10-04 |
1999-07-21 |
Merck & Co., Inc |
S�v� alendronat form�lasyonlar�
|
JP2824453B2
(ja)
*
|
1996-10-15 |
1998-11-11 |
株式会社ワカ製作所 |
コネクター
|
CA2197267C
(en)
*
|
1997-02-11 |
2000-02-08 |
Yong Tao |
Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
|
IL122009A0
(en)
*
|
1997-10-21 |
1998-03-10 |
Unipharm Ltd |
Salt of a bisphosphonic acid derivative
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
EP1088333A4
(en)
|
1998-06-24 |
2005-08-10 |
Merck & Co Inc |
METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
|
US6008207A
(en)
*
|
1998-08-13 |
1999-12-28 |
Merck & Co., Inc. |
Anhydrous alendronate monosodium salt formulations
|
PL346347A1
(en)
*
|
1998-08-27 |
2002-02-11 |
Teva Pharma |
Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
EP1702924A3
(en)
*
|
1998-08-27 |
2007-07-18 |
Teva Pharmaceutical Industries Ltd |
Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
US6331533B1
(en)
|
1998-11-16 |
2001-12-18 |
Merck & Co., Inc. |
Method for inhibiting dental resorptive lesions
|
US6160165A
(en)
*
|
1998-12-10 |
2000-12-12 |
Aesgen, Inc. |
Method for preparation of disodium pamidronate
|
US6794536B1
(en)
|
1998-12-10 |
2004-09-21 |
Aesqen, Inc. |
Method for preparation of disodium pamidronate
|
US6963008B2
(en)
*
|
1999-07-19 |
2005-11-08 |
Teva Pharmaceutical Industries Ltd. |
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
ES2153794B1
(es)
*
|
1999-08-06 |
2001-10-16 |
Medichem Sa |
Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
|
AR021347A1
(es)
*
|
1999-10-20 |
2002-07-17 |
Cipla Ltd |
Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
|
AU7902800A
(en)
*
|
1999-10-26 |
2001-05-08 |
A/S Gea Farmaceutisk Fabrik |
Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US6558702B2
(en)
|
2001-04-13 |
2003-05-06 |
Alkermes Controlled Therapeutics, Inc. |
Method of modifying the release profile of sustained release compositions
|
US20060269602A1
(en)
*
|
2001-04-13 |
2006-11-30 |
Dasch James R |
Method of modifying the release profile of sustained release compositions
|
TR200101250A2
(tr)
*
|
2001-05-10 |
2003-04-21 |
E�S Eczaciba�I �Zg�N K�Myasal �R�Nler Sanay� A.�. |
4-amino-1-hidroksibutiliden-1,1-bifosfonik asit veya tuzlarının hazırlanmasına ilişkin proses
|
CA2372450A1
(en)
*
|
2001-05-10 |
2001-09-19 |
Pharmaceutical Partners Of Canada Inc. |
Liquid injectable formulation of disodium pamidronate
|
GB2383042A
(en)
*
|
2001-10-18 |
2003-06-18 |
Cipla Ltd |
Amorphous alendronate sodium
|
CN100479823C
(zh)
*
|
2001-12-21 |
2009-04-22 |
宝洁公司 |
双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
|
US20050070504A1
(en)
*
|
2001-12-21 |
2005-03-31 |
The Procter & Gamble Co. |
Risedronate compositions and their methods of use
|
AU2002364051A1
(en)
*
|
2002-01-24 |
2003-09-02 |
Children's Medical Center Corporation |
Anti-cancer combination and use thereof
|
ITMI20020146A1
(it)
*
|
2002-01-29 |
2003-07-29 |
Lyogen Ltd |
Alendronato monosodico amorfo e processo per la sua preparazione
|
ITMI20020908A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione di sodio alendronato
|
ES2532393T3
(es)
*
|
2002-05-10 |
2015-03-26 |
F. Hoffmann-La Roche Ag |
Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
|
US7038083B2
(en)
|
2002-05-17 |
2006-05-02 |
Teva Pharmaceutical Industries, Ltd. |
Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons
|
EP1513523A1
(en)
*
|
2002-06-06 |
2005-03-16 |
Merck Frosst Canada & Co. |
1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
|
JP4485117B2
(ja)
*
|
2002-06-27 |
2010-06-16 |
日東電工株式会社 |
保護剥離用フィルム
|
JP2006504679A
(ja)
*
|
2002-08-28 |
2006-02-09 |
メルク フロスト カナダ アンド カンパニー |
緑内障の治療においてep4受容体作動薬として使用するためのオキサゾリジン−2−オンおよびチアゾリジン−2−オン誘導体
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
NZ536273A
(en)
*
|
2002-12-20 |
2007-08-31 |
Hoffmann La Roche |
High dose ibandronate formulation
|
US20040206932A1
(en)
*
|
2002-12-30 |
2004-10-21 |
Abuelyaman Ahmed S. |
Compositions including polymerizable bisphosphonic acids and methods
|
HUP0300227A2
(hu)
*
|
2003-01-28 |
2004-09-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
|
CA2535556C
(en)
*
|
2003-08-12 |
2014-01-07 |
3M Innovative Properties Company |
Self-etching dental compositions and methods
|
CA2535359A1
(en)
|
2003-08-21 |
2005-03-03 |
Merck Frosst Canada Ltd. |
Cathepsin cysteine protease inhibitors
|
DE602004024545D1
(de)
|
2003-08-21 |
2010-01-21 |
Sun Pharmaceuticals Ind Ltd |
Indungen
|
WO2005027921A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
|
WO2005035542A1
(en)
*
|
2003-10-14 |
2005-04-21 |
Pliva-Istrazivanje I Razvoj D.O.O. |
Solid-state form of alendronate sodium and preparation thereof
|
US20050261250A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Merck & Co., Inc., |
Compositions and methods for inhibiting bone resorption
|
ATE475412T1
(de)
|
2004-05-24 |
2010-08-15 |
Warner Chilcott Co Llc |
Enterische feste orale dosierform eines bisphosphonats mit einem chelate
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US8465284B2
(en)
*
|
2004-07-08 |
2013-06-18 |
3M Innovative Properties Company |
Dental methods, compositions, and kits including acid-sensitive dyes
|
WO2006020760A1
(en)
*
|
2004-08-11 |
2006-02-23 |
3M Innovative Properties Company |
Self-adhesive compositions including a plurality of acidic compounds
|
US7361761B2
(en)
*
|
2004-09-28 |
2008-04-22 |
Orchid Chemicals & Pharmaceuticals Ltd. |
Process for the preparation of bisphosphonic acid
|
US7214818B2
(en)
|
2004-10-29 |
2007-05-08 |
Hoffmann-La Roche Inc. |
Method for synthesizing bisphosphonate
|
CN1304401C
(zh)
*
|
2004-12-28 |
2007-03-14 |
浙江工业大学 |
一种阿伦膦酸的制备方法
|
PL1855674T3
(pl)
|
2005-03-02 |
2015-01-30 |
Merck Sharp & Dohme |
Kompozycja do hamowania katepsyny K
|
US8158153B2
(en)
*
|
2005-03-17 |
2012-04-17 |
Alkermes Pharma Ireland Limited |
Nanoparticulate bisphosphonate compositions
|
WO2006134603A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Jubilant Organosys Limited |
Process for producing bisphosphonic acids and forms thereof
|
AR054673A1
(es)
|
2005-07-28 |
2007-07-11 |
Gador Sa |
Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
|
US8003820B2
(en)
*
|
2005-10-20 |
2011-08-23 |
Dr. Reddy's Laboratories Limited |
Process for preparing bisphosphonic acids
|
JP5001292B2
(ja)
|
2005-10-31 |
2012-08-15 |
キャボット コーポレイション |
変性着色剤及び変性着色剤を含むインクジェットインキ組成物
|
PT1803727E
(pt)
*
|
2005-12-27 |
2009-06-15 |
Ipca Lab Ltd |
Processo melhorado para o fabrico de ácido 4-amino-hidroxibutilideno-1,1 bisfosfónico e seus sais
|
WO2007083240A2
(en)
|
2006-01-20 |
2007-07-26 |
Aurobindo Pharma Limited |
An improved process for the preparation of bisphosphonic acids
|
CA2570949A1
(en)
*
|
2006-12-12 |
2008-06-12 |
Apotex Pharmachem Inc. |
Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
|
CN101557791B
(zh)
|
2006-12-13 |
2013-05-22 |
3M创新有限公司 |
使用具有酸性组分和可光漂白染料的牙科用组合物的方法
|
WO2008125483A2
(en)
|
2007-04-11 |
2008-10-23 |
F. Hoffmann-La Roche Ag |
Multi step synthesis of ibandronate
|
WO2008157050A1
(en)
*
|
2007-06-19 |
2008-12-24 |
Albemarle Corporation |
Processes for manufacturing bisphosphonic acids
|
WO2009050731A2
(en)
*
|
2007-06-20 |
2009-04-23 |
Alkem Laboratories Ltd |
Novel process for preparing risedronic acid
|
US20090170815A1
(en)
*
|
2007-12-28 |
2009-07-02 |
Roxane Laboratories Incorporated. |
Alendronate oral liquid formulations
|
WO2009100107A2
(en)
*
|
2008-02-05 |
2009-08-13 |
Actavis Group Ptc Ehf |
Alendronate formulations, method of making and method of use thereof
|
WO2010003704A2
(en)
*
|
2008-07-11 |
2010-01-14 |
Synthon B.V. |
Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
|
US20100130746A1
(en)
*
|
2008-11-26 |
2010-05-27 |
Martin Kas |
Process for Making Zoledronic Acid
|
WO2010143193A1
(en)
|
2009-06-11 |
2010-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
WO2011023280A1
(en)
|
2009-08-28 |
2011-03-03 |
Synthon B.V. |
Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
|
JP5489126B2
(ja)
|
2009-09-30 |
2014-05-14 |
大日本印刷株式会社 |
インク組成物
|
CA2738045C
(en)
|
2010-05-28 |
2019-02-19 |
Simon Fraser University |
Conjugate compounds, methods of making same, and uses thereof
|
EP2609101B1
(en)
|
2010-07-14 |
2015-01-28 |
Pharmathen S.A. |
Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
|
EP3378906A1
(en)
|
2010-07-30 |
2018-09-26 |
Cabot Corporation |
Inkjet composition
|
TR201903835T4
(tr)
|
2010-12-06 |
2019-04-22 |
Effrx Pharmaceuticals Sa |
Hızlı çözünme özelliklerine sahip stabil efervesan bifosfonat formülasyonları.
|
KR20140009266A
(ko)
|
2010-12-27 |
2014-01-22 |
다이니폰 인사츠 가부시키가이샤 |
잉크젯 기록 방법
|
WO2012112363A1
(en)
|
2011-02-14 |
2012-08-23 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2012132403A1
(ja)
|
2011-03-29 |
2012-10-04 |
大日本印刷株式会社 |
インクジェット記録方法、およびインクジェット記録用インクセット
|
EP2731591B1
(en)
|
2011-07-13 |
2020-06-17 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
|
GB201200868D0
(en)
|
2012-01-19 |
2012-02-29 |
Depuy Int Ltd |
Bone filler composition
|
JP5722860B2
(ja)
|
2012-10-11 |
2015-05-27 |
株式会社Dnpファインケミカル |
水性インクジェット受理溶液、この受理溶液を含むインクセット及びこのインクセットを用いたインクジェット記録方法
|
AU2014332250B2
(en)
|
2013-10-08 |
2018-07-19 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP5779630B2
(ja)
|
2013-11-27 |
2015-09-16 |
株式会社Dnpファインケミカル |
インクジェット記録用インク組成物、及びその製造方法、並びに、インクジェット記録方法
|
JP5676734B1
(ja)
|
2013-12-27 |
2015-02-25 |
株式会社Dnpファインケミカル |
インクジェット記録用インク組成物、インクジェット記録方法、及び印刷物の製造方法
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
EP3148587B1
(en)
|
2014-05-30 |
2021-02-24 |
Pfizer Inc |
Carbonitrile derivatives as selective androgen receptor modulators
|
US9650414B1
(en)
|
2014-05-30 |
2017-05-16 |
Simon Fraser University |
Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
|
CN104072538A
(zh)
*
|
2014-07-10 |
2014-10-01 |
陕西汉江药业集团股份有限公司 |
一种双膦酸盐类药物的合成方法
|
WO2016199111A1
(en)
|
2015-06-12 |
2016-12-15 |
Simon Fraser University |
Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
|
EP3827010A4
(en)
|
2018-07-23 |
2022-03-16 |
Brise Pharmaceuticals Co., Ltd. |
BISPHOSPHONATE-DRUG CONJUGATES
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|